Identifying new therapies for Neurofibromatosis Type 1 cover art

Identifying new therapies for Neurofibromatosis Type 1

Identifying new therapies for Neurofibromatosis Type 1

Listen for free

View show details

About this listen

Neurofibromatosis Type 1 (NF1) is a neurodevelopmental disease which affects about 100,000 people in the US. Around 80% of these patients experience cognitive and intellectual impairments which are unaffected by currently approved therapies for NF1. A recent genetic study from our lab identified an association between the NF1 disease and a receptor protein called metabotropic glutamate receptor 7 (mGlu7). This project investigates how using small molecules to augment mGlu7 function could help identify new therapies for NF1 patients struggling with cognitive impairments.

Featuring: Harrison Parent, Ph.D. Candidate- Niswender Lab, Department of Pharmacology, Vanderbilt University School of Medicine

Interviewer: Colleen Niswender, Ph.D., Associate Professor of Pharmacology; Director of Molecular Pharmacology, Warren Center for Neuroscience Drug Discovery, and a Vanderbilt Kennedy Center Member
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.